Autor:	Steve Chaplin, Andrew Krentz
Rok vydání:	2008
Předmět:	business.industry Sitagliptin education medicine Pharmacology (medical) Pharmacology (nursing) Type 2 diabetes Pharmacology Adverse effect medicine.disease business Dipeptidyl peptidase-4 medicine.drug
Zdroj:	Prescriber. 19:26-29
ISSN:	1931-2253 0959-6682
DOI:	10.1002/psb.174
Popis:	Sitagliptin (Januvia) is the first of a new class of drugs in the treatment of type 2 diabetes. Here, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Dr Krentz comments on its potential place in the treatment of type 2 diabetes. Copyright © 2008 Wiley Interface Ltd
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0c496229cdebf110c0ca16d7eb4d931c https://doi.org/10.1002/psb.174 Zobrazit plný text záznamu Plný text